October 19, 2011 -- Shenzhen Hepalink Pharma, a maker of heparin products, reported its Q3 profits fell 58% to 148 million RMB ($23 million). Hepalink blamed the shortfall on a drop in the price of heparin API. In the past, Hepalink was the only China heparin API company whose products were certified by the FDA. It lost that advantage when a competitor was also granted FDA certification. More details....
Stock Symbol: (SHE: 002399)
